Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2-mRNA-LNP vaccine
- Development stage
- Preclinical
- Lead developer
- Virogin Biotech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Parenteral
01
Overview
The HER2-mRNA-LNP vaccine is an experimental mRNA-based cancer vaccine encapsulated in lipid nanoparticles (LNPs) designed to target Human Epidermal Growth Factor Receptor 2 (HER2). The vaccine functions by delivering mRNA encoding the HER2 antigen into host cells, which then express the protein to stimulate a systemic, HER2-specific immune response. Preclinical data presented at ASTRO 2025 demonstrated that the vaccine significantly inhibits tumor growth in HER2-overexpressing Lewis Lung Carcinoma (LLC) mouse models. The study also highlighted a synergistic anti-tumor effect when the vaccine is combined with radiotherapy, which appears to enhance the immune response and alter the tumor immune microenvironment. Safety evaluations in animal models indicated no significant toxicity in major organs or blood parameters.
- Other names
- HER2-mRNA-LNPHER-2-mRNA-LNPHER 2-mRNA-LNP
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HER2-mRNA-LNP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2-mRNA-LNP vaccine.